Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.
Mahmoud IzadiAnavasadat Sadr Hashemi NejadMaedeh MoazenchiSafdar MasoumiAli RabbaniFarzad KompaniAmir Abbas Hedayati AslFatemeh Abbasi KakroodiNeda JaroughiMohammad Ali Mohseni MeybodiAria SetoodehFarzaneh AbbasiSeyedeh Esmat HosseiniFatemeh Moeini NiaReza Salman YazdiRoghayeh NavabiEnsiyeh Hajizadeh-SaffarHossein BaharvandPublished in: Stem cell research & therapy (2022)
This clinical trial was registered at the Iranian Registry of Clinical Trials (IRCT) with the identifier IRCT ID: IRCT2016070428786N1 registered on August 20, 2016 (Retrospectively registered) ( https://en.irct.ir/trial/23256 ) and at the U.S. National Institutes of Health (ClinicalTrials.gov) with the related identifier NCT04078308 registered on September 6, 2019 (Retrospectively registered). ( https://clinicaltrials.gov/ct2/show/NCT04078308 ).
Keyphrases
- clinical trial
- phase ii
- double blind
- phase iii
- newly diagnosed
- placebo controlled
- open label
- type diabetes
- study protocol
- end stage renal disease
- healthcare
- public health
- mesenchymal stem cells
- ejection fraction
- phase ii study
- chronic kidney disease
- prognostic factors
- cardiovascular disease
- bone marrow
- quality improvement
- computed tomography
- peritoneal dialysis
- squamous cell carcinoma
- insulin resistance
- climate change
- positron emission tomography
- cell therapy
- image quality